Skye Bioscience, Inc.

SKYE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$26,567-$37,645-$19,482-$8,522
Dep. & Amort.$299$124$115$34
Deferred Tax$0$0$0$0
Stock-Based Comp.$8,317$988$629$869
Change in WC-$2,629-$469-$762$647
Other Non-Cash-$4,658$23,050$6,755$497
Operating Cash Flow-$25,237-$13,952-$12,744-$6,475
Investing Activities
PP&E Inv.-$1,604-$13-$28-$91
Net Acquisitions$0$0$5,309$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$1,358$0$0$0
Other Inv. Act.$0$6,609-$66$0
Investing Cash Flow-$246$6,596$5,214-$91
Financing Activities
Debt Repay.$0$4,714-$211$0
Stock Issued$83,557$11,735$2$6,063
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$6-$6$0$7,017
Financing Cash Flow$83,562$16,443-$209$13,079
Forex Effect$0$0$0$0
Net Chg. in Cash$58,079$9,088-$7,738$6,514
Supplemental Information
Beg. Cash$10,337$1,249$8,988$2,474
End Cash$68,416$10,337$1,249$8,988
Free Cash Flow-$26,842-$13,965-$12,772-$6,566
Skye Bioscience, Inc. (SKYE) Financial Statements & Key Stats | AlphaPilot